7.00
Precedente Chiudi:
$6.96
Aprire:
$7
Volume 24 ore:
969.88K
Relative Volume:
0.99
Capitalizzazione di mercato:
$350.72M
Reddito:
$124.00K
Utile/perdita netta:
$-49.99M
Rapporto P/E:
-4.142
EPS:
-1.69
Flusso di cassa netto:
$-31.03M
1 W Prestazione:
+1.16%
1M Prestazione:
+44.33%
6M Prestazione:
+1.60%
1 anno Prestazione:
+10.06%
Candel Therapeutics Inc Stock (CADL) Company Profile
Nome
Candel Therapeutics Inc
Settore
Industria
Telefono
617-916-5445
Indirizzo
117 KENDRICK STREET, NEEDHAM
Confronta CADL con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CADL
Candel Therapeutics Inc
|
7.00 | 348.71M | 124.00K | -49.99M | -31.03M | -1.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-30 | Ripresa | H.C. Wainwright | Buy |
2025-02-20 | Iniziato | Citigroup | Buy |
2025-02-19 | Iniziato | Canaccord Genuity | Buy |
2025-02-07 | Iniziato | BofA Securities | Buy |
2022-12-02 | Iniziato | H.C. Wainwright | Buy |
2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
2021-08-23 | Iniziato | Credit Suisse | Outperform |
2021-08-23 | Iniziato | Jefferies | Buy |
2021-08-23 | Iniziato | UBS | Buy |
Mostra tutto
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Candel Therapeutics' CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment - citybuzz -
Can Candel Therapeutics Inc. stock recover from recent declineExceptional return forecasts - jammulinksnews.com
Small cap wrap: Blockmate Ventures, Candel Therapeutics, HIVE Digital, American Resources... - Proactive financial news
Candel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409 - Proactive financial news
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer - GlobeNewswire
Revolutionary Pancreatic Cancer Treatment Shows 31.4-Month Survival, Secures Critical EU Designation - Stock Titan
Is Candel Therapeutics Inc. a good long term investmentSuperior profit margins - jammulinksnews.com
Candel Therapeutics Inc. Stock Analysis and ForecastSkyrocketing returns - jammulinksnews.com
What drives Candel Therapeutics Inc. stock priceTremendous portfolio expansion - jammulinksnews.com
What analysts say about Candel Therapeutics Inc. stockFree Stock Market Knowledge Sharing - Autocar Professional
(CADL) Trading Report - news.stocktradersdaily.com
What makes Candel Therapeutics Inc. stock price move sharplyShort Squeeze Radar - beatles.ru
Candel Therapeutics (CADL) Shares Soar 9.60% - AInvest
Candel Therapeutics (CADL) Has a New Rating from Freedom Capital Markets - The Globe and Mail
Freedom Broker initiates coverage on Candel Therapeutics stock with Buy rating - Investing.com Nigeria
Freedom Broker initiates coverage on Candel Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
(CADL) Investment Report - news.stocktradersdaily.com
Brookline Capital Initiates Candel Therapeutics(CADL.US) With Buy Rating, Announces Target Price $25 - 富途牛牛
Candel Therapeutics Added to Russell Indexes, Analysts Forecast Upside of 319.85% - AInvest
Candel Therapeutics added to multiple Russell value indexes By Investing.com - Investing.com South Africa
Brookline Capital initiates Candel Therapeutics stock with Buy rating, $25 target - Investing.com Nigeria
Candel Therapeutics Added To Multiple Russell Value Indexes In 2025 Reconstitution - 富途牛牛
Market movers: Meta, Nvidia, Candel Therapeutics, Ocean Power Technologies... - Proactive financial news
Candel Therapeutics: Russell Inclusion and Clinical Catalysts Drive Biotech Upside - AInvest
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution - The Manila Times
Candel Therapeutics added to multiple Russell value indexes - Investing.com
Candel Therapeutics, Inc. Gains Inclusion in Multiple Russell Value Indexes During 2025 Annual Reconstitution - Quiver Quantitative
Candel Therapeutics Expands Russell Index Presence with - GlobeNewswire
Candel Therapeutics expands Russell Index presence following 2025 reconstitution - Proactive financial news
Candel Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com India
One Candel Therapeutics Insider Raised Stake By 22% In Previous Year - Yahoo Finance
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Market movers: Carnival, Uber, Ideal Power, Candel Therapeutics... - Proactive Investors
Candel Therapeutics announces $15M direct offering to support CAN-2409 launch preparations - Proactive Investors
Candel Therapeutics names Charles Schoch as CFO after interim tenure - Proactive financial news
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer - The Globe and Mail
Trend Tracker for (CADL) - news.stocktradersdaily.com
Candel Therapeutics Elects New Directors at Annual Meeting - TipRanks
Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st
Neoantigen Cancer Vaccines Industry Analysis Report 2025 with Tariff-Adjusted Forecasts and Analytics to 2030 - GlobeNewswire
Candel Therapeutics Inc Azioni (CADL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):